Short Seller Soren Aandahl Chases Targets With New Hedge Fund
Sofia Horta e Costa, 03 May 2021
Activist short seller Soren Aandahl is launching his first hedge fund, with a mandate to find accounting malpractice and overvalued stocks all over the world.
The Blue Orca Global Activism Fund starts trading Monday with $25 million in assets under management, according to Aandahl, who founded Blue Orca Capital three years ago in Austin, Texas. He says he’s lining up another potential $30 million in committed capital. The fund will pursue targets globally, using a market-neutral strategy to seek profits regardless of whether global stocks are in a downturn or uptrend, said Aandahl. Continue reading “Article: Short Seller Soren Aandahl Chases Targets With New Hedge Fund”
Naked Short Selling: The Truth Is Much Worse Than You Have Been Told
By James Stafford – Feb 02, 2021, 3:20 PM CST, OilPrice.com
There is a massive threat to our capital markets, the free market in general, and fair dealings overall. And no, it’s not China. It’s a homegrown threat that everyone has been afraid to talk about.
Until now. That fear has now turned into rage.
The naked truth is this: Investors stand no chance in the face of naked short sellers. It’s a game rigged in the favor of a sophisticated short cartel and Wall Street giants.
Continue reading “Naked Short Selling: The Truth Is Much Worse Than You Have Been Told”
A famed short-seller explains why he’s betting big against a Chinese tech stock that has seen a ‘crazy stupid’ 320% gain in 2020
Saloni Sardana, 22 August 2020
Famed short-seller Andrew Left is aggressively shorting a “crazy stupid” Chinese stock that has gained more than 320% on the New York Stock exchange in 2020, as he believes it has exaggerated its earnings and will eventually be delisted. The activist short-seller and founder of Citron Capital, told Business Insider that he believes that the earnings of GSX Techedu are grossly inflated “anywhere between 50 to 80%.” GSX, which is an online education provider, has surged despite a number of claims by various short-sellers casting doubt on the company’s performance. Continue reading “Article: A famed short-seller explains why he’s betting big against a Chinese tech stock that has seen a ‘crazy stupid’ 320% gain in 2020”
Andrew Edward Left is an activist short seller, author and editor of the online investment newsletter Citron Research, formerly StockLemon.com. Left is known for advising investors on short selling and has often appeared on various media outlets such as CNBC and Bloomberg to talk about his opinions on stocks. In 2016, Left was banned for five years by the Hong Kong Market Misconduct Tribunal for disclosing false or misleading information, and so inducing transactions under the Securities and Futures Ordinance.
Chart and Articles for Peloton Today
Comment: Watch LEFT and his $5 target on stock its $44. Like i said he put out his BullShit report the people panic and sell and he makes a quick profit you know they are not short anymore. FOLLOW HIS SELL TICKETS in PTON I bet you will see the Sells and 10 minutes after the attack and report is out THEY COVER
Citron Research Further Criticizes Inovio Pharmaceuticals, Inc.; Investors Who Lost Money Should Contact Block & Leviton LLP Who Filed First Shareholder Lawsuit
Global Newswire, 27 April 2020
BOSTON, April 27, 2020 (GLOBE NEWSWIRE) — Today, research analyst Citron Research published a report calling Inovio (INO) “The COVID-19 Version of Theranos,” in which Citron slashed its target price for Inovio common stock by 93%.
Dr Left has a $1 target stock is $11 ( you know he shorted at $16-17 and covered already never waiting for his $1 target SHORT AND DISTORT for a quick profit
Continue reading “Release: Andrew Left Naked Short Selling Inovio? Block & Leviton in Collusion Defaming and Committing Tortious Interference?”
Who Needs New Year’s Resolutions After 43%
Returns? Andrew Left Does.
Alicia McElhaney, 07 January 2020
In 2019, short-seller Andrew Left’s Citron Capital returned a searing 43.3 percent, net of fees. But instead of wallowing in glory, Left plans to make some changes to his investment style in 2020. Foremost, Left intends to zero in on small-cap stocks rather than betting on (or against) major names like Shopify and Tesla, he told Institutional Investor Tuesday.
“My job is not to be right; my job is to generate returns,” Left said. “I’m not doing that by shorting high-concept big stocks.” Left shared the firm’s 2019 performance in an investor letter Monday, where he also reflected on recent big bets and what’s ahead. He learned two major lessons in 2019, according to the letter. The first: “Always go back to Citron’s proficiency – exposing fraud.”
Continue reading “Article: Who Needs New Year’s Resolutions After 43% Returns? Andrew Left Does.”
One of Wall Street’s most notorious short-sellers says Peloton will plummet 86%, citing ‘intense’ competition (PTON)
MarketInsider, 10 December 2019
- Citron Research, run by the famed short-seller Andrew Left, slapped Peloton with a $5 price target on Tuesday.
- That would imply an 86% drop from Monday’s close of $34.77.
- Citron argued that the losses would come amid “intense” competition that’s mounting.
- Shares of Peloton fell as much as 9.1% on Tuesday.
Comment: Yelling fire in a crowded theatre is a crime A short and distort SELL REPORT How about selling his sell tickets IS he still short? his target is $5 right I bet he covered 10 min after his report . Andrew Left should be under investigation. His recommendations should be compared to his positions.
Bausch Health jumps after short seller says stock could double
Cristin Flanagan, 15 October 2019
Shares of Bausch Health Cos. jumped as much as 5.5 per cent intraday after a short-seller changed his tune and said the stock could nearly double. Also, Bausch shed another bear as Wells Fargo realigned its coverage. Andrew Left’s Citron Research set a price target of US$40, more than 80 per cent above current trading. The report comes more than four years after the short-seller’s 2015 call, when Left accused Bausch, then known as Valeant Pharmaceuticals, of being “Enron part deux.”
Bausch shares have come down more than 90 per cent from 2015. The stock “still trades with a ‘Valeant discount’ despite new management’s 180-degree turn,” the Citron report said. Bausch’s Nov. 4 earnings may be when Wall Street finally takes notice, it added.
Continue reading “Article: Bausch Health jumps after short seller says stock could double”
Citron Calls Bausch Health — Formerly Valeant — The ‘Textbook Turnaround’
Wayne Duggan, 15 October 2019
Three years after Citron Research called Valeant the “pharmaceutical Enron,” the firm said Tuesday that it’s time to give Valeant successor Bausch Health Companies Inc BHC 0.06% the credit it is due for its rebranding and turnaround efforts.
On Tuesday, Citron Research’s Andrew Left said CEO Joe Papa has done a spectacular job since taking over less than four years ago. In the past three years alone, management has paid down about $8 billion in debt, vastly improving the company’s balance sheet and putting them in a position of financial flexibility.
“In 2019, the debt has become manageable and the company is gaining momentum with recent, successful launches of new drugs, consistent with its ‘pivot to offense,’” Left said.
Continue reading “Article: Citron Calls Bausch Health — Formerly Valeant — The ‘Textbook Turnaround’”
Citron’s Andrew Left slams Jumia as a ‘fraud,’ accuses company of ‘financial colonialism’ in latest video
MarketWatch, 29 May 2019
Citron Research’s Andrew Left, a noted short seller, is once again slamming Jumia Technologies AG as a “fraud,” this time in a video that includes footage of what he says are former employees who accuse the company of placing fake orders.
Comment: Down from $36 to $3 based on a naked short selling campaign apparently led by Andrew Left.
Shopify Shares Fall Fast Following Report From Short Seller
KEVIN CURRAN, 04 April 2019
Shares fell over 3% after the report’s release, cutting into the Canadian e-commerce company’s 50% gain to kick off 2019. “I still think they are best in class,” Andrew Left, Citron Research’s executive editor, acknowledged in an interview with Real Money. “It’s just that when you have a PE ratio over 300, its being priced like nothing bad can happen.”
He cited the emergence of competition from Square’s (SQ) online store, Facebook’s (FB) Instagram checkout, and the rumored launch of a Microsoft’s (MSFT) shopping competitor, as indicators that could deflate the stock. “This is a company that is priced for hyper growth. If they lose 15% of their base, their multiple is going to get smacked,” Left commented.
Continue reading “Article: Shopify Shares Fall Fast Following Report From Short Seller”
Shopify dives after short-seller Andrew Left of Citron Research shorts the e-commerce stock
Ellen Kelleher, 04 April 2019
Shares of Shopify Inc (NYSE:SHOP) tumbled Thursday after famed short-seller Andrew Left of Citron Research went bearish and urged investors to short the Canadian e-commerce company. In a research note, Left and his team make the case that their newly-adopted short position stems from a “perfect storm” of business setbacks that will knock Shopify “off its high wire to $100 in the next 12 months.”
Growing fearful about Left’s predictions, investors sent Shopify shares down 6% to $192.75 in afternoon trade. In the past month, Citron says a lot has changed for Shopify as Square Inc (NYSE:SQ) announced it is revamping its online store; Mailchimp ended its partnership with the e-commerce site; and news surfaced that Microsoft (NASDAQ:MSFT) is launching a competitive offering to Shopify.
Continue reading “Article: Shopify dives after short-seller Andrew Left of Citron Research shorts the e-commerce stock”
Short-seller Andrew Left to appeal against Hong Kong market ban
Reuters, 26 February 2019
HONG KONG (Reuters) – U.S. short seller Andrew Left lost his legal bid on Tuesday to overturn a five-year ban from Hong Kong’s financial markets and a fine for market manipulation.
Left, founder of U.S.-based short-seller Citron Research, was banned in 2016 after he was found culpable of market misconduct in connection with the publication of a research report on Chinese property developer China Evergrande Group.
Short seller Andrew Left has his doubts about Canadian pot stocks, says he’s betting against Canopy
Thomas Franck, 14 November 2018
Citron Research’s Andrew left reiterated his bet against the Canadian cannabis industry Wendesday, telling CNBC that he’s short Canopy Growth and Cronos Group in addition to his already disclosed wager against Tilray.
Fielding a question from “Halftime Report” host Scott Wapner, Left said his doubts on the space aren’t confined to just one company. “I’m also short Cronos, I’m short Canopy, I’m short Tilray. So I’m short a basket of the names,” he said. “Once the U.S. licensed producers come on — the faster it becomes legal in the U.S., the quicker the Canada names go lower.”
“They won’t get the exposure in the U.S., they’re not players internationally,” Left added. “I don’t care how many press releases they put out, they’re not going to be shipping cannabis from Canada to Australia. Not happening.”
Continue reading “Article: Short seller Andrew Left has his doubts about Canadian pot stocks, says he’s betting against Canopy”